Jun Chang Professor

Pharmaceutical Sciences/Division of Pharmacy/Industrial Pharmaceutical Science

장준 프로필 사진
Professor Jun Chang, at the Department of Pharmacy, is an expert of vaccine research against human respiratory syncytial virus and influenza virus infection. He received his Ph.D. degree at the POSTECH, and he is developing prophylactic vaccines against respiratory viruses. He has published more than 50 research articles on international SCI journals. 
  • Director, Research Institute of Pharmaceutical Science
  • Pharmaceutical Science Building B #201
  • 02-3277-2549
  • Research Interests
    • T CELL IMMUNITY, UNIVERSAL INFLUENZA VACCINE, RESPIRATORY SYNCYTIAL VIRUS
Research Record
  • Nucleoprotein vaccine induces cross-protective cytotoxic T lymphocytes against both lineages of influenza B virus Clinical and Experimental Vaccine Research, 2019, v.8 no.1, 54~63
    KCI dColl.
  • Single mucosal vaccination targeting nucleoprotein provides broad protection against two lineages of influenza B virus Antiviral Research, 2019, v.163, 19-28
    SCIE Scopus dColl.
  • Sublingual Immunization With an RSV G Glycoprotein Fragment Primes IL-17-Mediated Immunopathology Upon Respiratory Syncytial Virus Infection FRONTIERS IN IMMUNOLOGY, 2019, v.10, 567
    SCIE Scopus dColl.
  • Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus PLOS ONE, 2019, v.14 no.7, e0220196
    SCIE Scopus dColl.
  • Development of Safe and Effective RSV Vaccine by Modified CD4 Epitope in G Protein Core Fragment (Gcf) PLOS ONE, 2014, v.9 no.4
    SCIE Scopus dColl.
  • Induction of long-term immunity against respiratory syncytial virus glycoprotein by an osmotic polymeric nanocarrier Acta Biomaterialia, 2014, v.10 no.11, 4606-4617
    SCIE Scopus dColl.
  • Intranasal Adenovirus-Vectored Vaccine for Induction of Long-Lasting Humoral Immunity-Mediated Broad Protection against Influenza in Mice JOURNAL OF VIROLOGY, 2014, v.88 no.17, 9693-9703
    SCIE Scopus dColl.
  • Fc-fused IL-7 provides broad antiviral effects against respiratory virus infections through IL-17A-producing pulmonary innate-like T cells Cell Reports Medicine, 2024, v.5 no.1, 101362
    SCIE Scopus dColl.
  • Vaccine Strategy That Enhances the Protective Efficacy of Systemic Immunization by Establishing Lung-Resident Memory CD8 T Cells Against Influenza Infection Immune Network, 2023, v.23 no.4, e32
    SCIE Scopus KCI dColl.
  • In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy Science Advances, 2022, v.8 no.3, eabj6901
    SCIE Scopus dColl.
  • A "Prime and Deploy" Strategy for Universal Influenza Vaccine Targeting Nucleoprotein Induces Lung-Resident Memory CD8 T cells IMMUNE NETWORK, 2021, v.21 no.4, e28
    SCIE Scopus KCI dColl.
  • Adenovirus Vectors: Excellent Tools for Vaccine Development Immune Network, 2021, v.21 no.1, 1-11
    SCIE Scopus KCI dColl.
  • Effective inactivated influenza vaccine for the elderly using a single-stranded RNA-based adjuvant SCIENTIFIC REPORTS, 2021, v.11 no.1, 11981
    SCIE Scopus dColl.
  • IDO1 scavenges reactive oxygen species in myeloid-derived suppressor cells to prevent graft-versus-host disease Proceedings of the National Academy of Sciences of the United States of America, 2021, v.118 no.10, e2011170118
    SCIE Scopus dColl.
  • MHC Multimer: A Molecular Toolbox for Immunologists MOLECULES AND CELLS, 2021, v.44 no.5, 328-334
    SCIE Scopus KCI dColl.
  • Adjuvant incorporated lipid nanoparticles for enhanced mRNA-mediated cancer immunotherapy BIOMATERIALS SCIENCE, 2020, v.8 no.4, 1101-1105
    SCIE Scopus dColl.
  • Alveolar Macrophages Treated With Bacillus subtilis Spore Protect Mice Infected With Respiratory Syncytial Virus A2 FRONTIERS IN MICROBIOLOGY, 2019, v.10, 447
    SCIE Scopus dColl.
  • Plasmacytoid Dendritic Cells Contribute to the Production of IFN-beta via TLR7-MyD88-Dependent Pathway and CTL Priming during Respiratory Syncytial Virus Infection VIRUSES-BASEL, 2019, v.11 no.8, 730
    SCIE Scopus dColl.
  • Vaccine containing G protein fragment and recombinant baculovirus expressing M2 protein induces protective immunity to respiratory syncytial virus Clinical and Experimental Vaccine Research, 2019, v.8 no.1, 43~53
    KCI dColl.
  • Atherosclerosis is exacerbated by chitinase-3-like-1 in amyloid precursor protein transgenic mice THERANOSTICS, 2018, v.8 no.3, 749-766
    SCIE Scopus dColl.
  • Chaperna-Mediated Assembly of Ferritin-Based Middle East Respiratory Syndrome-Coronavirus Nanoparticles FRONTIERS IN IMMUNOLOGY, 2018, v.9
    SCIE Scopus dColl.
  • Effect of apoptosis-associated speck-like protein containing a caspase recruitment domain on vaccine efficacy: Overcoming the effects of its deficiency with aluminum hydroxide adjuvant MICROBIOLOGY AND IMMUNOLOGY, 2018, v.62 no.3, 176-186
    SCIE Scopus dColl.
  • Eliciting unnatural immune responses by activating cryptic epitopes in viral antigens FASEB JOURNAL, 2018, v.32 no.9, 4658-4669
    SCIE Scopus dColl.
  • Escape from thymic deletion and anti-leukemic effects of T cells specific for hematopoietic cell-restricted antigen Nature Communications, 2018, v.9 no.1, 225
    SCIE Scopus dColl.
  • Non-specific Effect of Vaccines: Immediate Protection against Respiratory Syncytial Virus Infection by a Live Attenuated Influenza Vaccine FRONTIERS IN MICROBIOLOGY, 2018, v.9, 83
    SCIE Scopus dColl.
  • Pan-Influenza A Protection by Prime-Boost Vaccination with Cold-Adapted Live-Attenuated Influenza Vaccine in a Mouse Model FRONTIERS IN IMMUNOLOGY, 2018, v.9, 116
    SCIE Scopus dColl.
  • Basophil-derived IL-6 regulates TH17 cell differentiation and CD4 T cell immunity Scientific Reports, 2017, v.7
    SCIE Scopus dColl.
  • Monoclonal Antibody against G Glycoprotein Increases Respiratory Syncytial Virus Clearance In Vivo and Prevents Vaccine-Enhanced Diseases PLOS ONE, 2017, v.12 no.1
    SCIE Scopus dColl.
  • Recombinant baculovirus-based vaccine expressing M2 protein induces protective CD8+ T-cell immunity against respiratory syncytial virus infection Journal of Microbiology, 2017, v.55 no.11, 900-908
    SCIE Scopus KCI dColl.
  • Universal vaccine against respiratory syncytial virus A and B subtypes PLOS ONE, 2017, v.12 no.4
    SCIE Scopus dColl.
  • miR-150-Mediated Foxo1 Regulation Programs CD8+ T Cell Differentiation Cell Reports, 2017, v.20 no.11, 2598-2611
    SCIE Scopus dColl.
  • Baculovirus displaying hemagglutinin elicits broad cross-protection against influenza in mice PLoS ONE, 2016, v.11 no.3
    SCIE Scopus dColl.
  • Cholera Toxin Promotes Th17 Cell Differentiation by Modulating Expression of Polarizing Cytokines and the Antigen-Presenting Potential of Dendritic Cells PLOS ONE, 2016, v.11 no.6
    SCIE Scopus dColl.
  • Fas-Associated Factor 1 Negatively Regulates the Antiviral Immune Response by Inhibiting Translocation of Interferon Regulatory Factor 3 to the Nucleus MOLECULAR AND CELLULAR BIOLOGY, 2016, v.36 no.7, 1136-1151
    SCIE Scopus dColl.
  • In hot pursuit of the first vaccine against respiratory syncytial virus Yonsei Medical Journal, 2016, v.57 no.4, 809-816
    SCIE Scopus KCI dColl.
  • Role of PD-1 in regulatory T cells during chronic virus infection JOURNAL OF IMMUNOLOGY, 2016, v.196
    SCIE Scopus dColl.
  • Sublingual immunization with Japanese encephalitis virus vaccine effectively induces immunity through both cellular and humoral immune responses in mice MICROBIOLOGY AND IMMUNOLOGY, 2016, v.60 no.12, 846-853
    SCIE Scopus dColl.
  • The recent ancestry of Middle East respiratory syndrome coronavirus in Korea has been shaped by recombination Scientific Reports, 2016, v.6
    SCIE Scopus dColl.
  • Co-transplantation of human fetal thymus, bone and CD34(+) cells into young adult immunodeficient NOD/SCID IL2R gamma(null) mice optimizes humanized mice that mount adaptive antibody responses CLINICAL IMMUNOLOGY, 2015, v.157 no.2, 156-165
    SCIE Scopus dColl.
  • Discrimination between Active and Latent Tuberculosis Based on Ratio of Antigen-Specific to Mitogen-Induced IP-10 Production JOURNAL OF CLINICAL MICROBIOLOGY, 2015, v.53 no.2, 504-510
    SCIE Scopus dColl.
  • Effect of respiratory syncytial virus on the growth of hepatocellular carcinoma cell-lines BMB REPORTS, 2015, v.48 no.10, 565-570
    SCIE KCI Scopus dColl.
  • Memory programming in CD8+T-cell differentiation is intrinsic and is not determined by CD4 help Nature Communications, 2015, v.6
    SCIE Scopus dColl.
  • PD-1 Upregulated on Regulatory T Cells during Chronic Virus Infection Enhances the Suppression of CD8(+) T Cell Immune Response via the Interaction with PD-L1 Expressed on CD8(+) T Cells JOURNAL OF IMMUNOLOGY, 2015, v.194 no.12, 5801-5811
    SCIE Scopus dColl.
  • Transplantation of human spleen into immunodeficient NOD/SCID IL2Rγnull mice generates humanized mice that improve functional B cell development Clinical Immunology, 2015, v.161 no.2, 308-315
    SCIE Scopus dColl.
  • Author Correction to Differentiation of antigen-specific T cells with limited functional capacity during Mycobacterium tuberculosis infection [Infection and Immunity, 82, 1, (2014) 132-139] Infection and Immunity, 2014, v.82 no.8, 3514
    SCIE Scopus dColl.
  • Differentiation of Antigen-Specific T Cells with Limited Functional Capacity during Mycobacterium tuberculosis Infection INFECTION AND IMMUNITY, 2014, v.82 no.1, 132-139
    SCIE Scopus dColl.
  • [학술지논문] Single mucosal vaccination targeting nucleoprotein provides broad protection against two lineages of influenza B virus ANTIVIRAL RESEARCH, 2019, v.163 no.1 , 19-28
    SCI
  • [학술지논문] Sublingual Immunization With an RSV G Glycoprotein Fragment Primes IL-17-Mediated Immunopathology Upon Respiratory Syncytial Virus Infection FRONTIERS IN IMMUNOLOGY, 2019, v.10 no.567 , 1-14
    SCIE
Courses
  • 2024-2nd

    • Immunology 강의 계획서 상세보기

      • Subject No 38958Class No 01
      • 3Year ( 3Credit , 3Hour) Mon 4~4 (PHM-A400) , Wed 3~3 (PHM-A404)
      • Major Requisite
    • Pharmaceutical Sciences and Experiment Ⅱ

      • Subject No 38964Class No 01
      • 3Year ( 2Credit , 3Hour) Tue 6~7 (PHM-A307)
      • Major Requisite
    • Pharmaceutical Sciences and Experiment Ⅱ

      • Subject No 38964Class No 02
      • 3Year ( 2Credit , 3Hour) Wed 6~7 (PHM-A307)
      • Major Requisite
    • Immunology 강의 계획서 상세보기

      • Subject No 39063Class No 01
      • 3Year ( 3Credit , 3Hour) Mon 5~5 (PHM-A400) , Wed 5~5 (PHM-A100-1)
    • Pharmaceutical Sciences and Experiment Ⅱ

      • Subject No 39069Class No 01
      • 3Year ( 2Credit , 3Hour) Mon 6~7 (PHM-A307)
      • Major Requisite
    • Advanced Pharmaceutical Microbiology

      • Subject No G16897Class No 01
      • Year ( 3Credit , 3Hour) Tue 2~3 (PHM-)
    • Understanding and Application of Bioinformatics and Chemoinformatics

      • Subject No G18091Class No 01
      • Year ( 3Credit , 3Hour) Fri 4~5 (PHM-)
  • 2024-1st

    • Immunology 강의 계획서 상세보기

      • Subject No 36201Class No 01
      • 4Year ( 3Credit , 3Hour) Mon 5~5 (POSCO551) , Wed 4~4 (PHM-A404)
    • Molecular Biology 강의 계획서 상세보기

      • Subject No 38935Class No 01
      • 2Year ( 3Credit , 3Hour) Tue 4~4 (POSCO) , Wed 5~5 (161)
    • Pharmaceutical Sciences and Experiment Ⅱ

      • Subject No 38964Class No 01
      • 3Year ( 2Credit , 3Hour) Mon 6~7 (PHM-A307)
      • Major Requisite
    • Pharmaceutical Sciences and Experiment Ⅱ

      • Subject No 38964Class No 02
      • 3Year ( 2Credit , 3Hour) Tue 6~7 (PHM-A307)
      • Major Requisite
    • Introduction to Pharmaceutical Research

      • Subject No 39045Class No 01
      • 2Year ( 1.5Credit , 1.5Hour) Thu 6~6 (PHM-A100-1)
    • Pharmaceutical Sciences and Experiment Ⅱ

      • Subject No 39069Class No 01
      • 3Year ( 2Credit , 3Hour) Wed 6~7 (PHM-A307)
      • Major Requisite
    • Infection Control and Molecular Mechanisms

      • Subject No G16858Class No 01
      • Year ( 3Credit , 3Hour) Fri 4~5 (PHM-)
  • 2023-2nd

  • 2023-1st

  • 2022-2nd

    • Molecular Biology

      • Subject No 36205Class No 01
      • 3Year ( 3Credit , 3Hour) Thu 2~2 (PHM-A100-1) , Fri 3~3 (POSCO552)
    • Molecular Biology

      • Subject No 36205Class No 02
      • 3Year ( 3Credit , 3Hour) Thu 3~3 (PHM-A100-1) , Fri 4~4 (POSCO552)
    • Pharmaceutical Experiment II

      • Subject No 37106Class No 01
      • 3Year ( 1.5Credit , 3Hour) Mon 6~7 (PHM-A307)
      • Major Requisite
    • Pharmaceutical Experiment II

      • Subject No 37106Class No 02
      • 3Year ( 1.5Credit , 3Hour) Tue 6~7 (PHM-A307)
      • Major Requisite
    • Pharmaceutical Experiment II

      • Subject No 37106Class No 03
      • 3Year ( 1.5Credit , 3Hour) Wed 6~7 (PHM-A307)
      • Major Requisite
    • Clinical Immunology

      • Subject No 37131Class No 01
      • 4Year ( 1.5Credit , 1.5Hour) Thu 6~6 (PHM-A100-1)
    • Honors research

    • Advanced Pharmaceutical Microbiology II

      • Subject No G16897Class No 01
      • Year ( 3Credit , 3Hour) Fri 6~7 (PHM-)
    • Understanding and application of Bioinformatics and Chemoinformatics

      • Subject No G18091Class No 01
      • Year ( 3Credit , 3Hour) Mon 2~3 (PHM-)
  • 2022-1st

    • Immunology

      • Subject No 36201Class No 01
      • 4Year ( 3Credit , 3Hour) Tue 4~4 , Thu 4~4
    • Immunology

      • Subject No 36201Class No 02
      • 4Year ( 3Credit , 3Hour) Tue 4~4 , Thu 4~4
    • Pharmaceutical Experiment II

      • Subject No 37106Class No 01
      • 3Year ( 1.5Credit , 3Hour) Wed 6~7 (PHM-A307)
      • Major Requisite
    • Pharmaceutical Experiment II

      • Subject No 37106Class No 02
      • 3Year ( 1.5Credit , 3Hour) Tue 6~7 (PHM-A307)
      • Major Requisite
    • Pharmaceutical Experiment II

      • Subject No 37106Class No 03
      • 3Year ( 1.5Credit , 3Hour) Mon 6~7 (PHM-A307)
      • Major Requisite
    • Infection control and molecular mechanisms

      • Subject No G16858Class No 01
      • Year ( 3Credit , 3Hour) Wed 2~3 (PHM-A204)
  • 2021-2nd

    • Molecular Biology

      • Subject No 36205Class No 01
      • 3Year ( 3Credit , 3Hour) Wed 5~5 , Fri 4~4
    • Molecular Biology

      • Subject No 36205Class No 02
      • 3Year ( 3Credit , 3Hour) Wed 4~4 , Fri 5~5
    • Pharmaceutical Experiment II

      • Subject No 37106Class No 01
      • 3Year ( 1.5Credit , 3Hour) Mon 6~9 (PHM-A307)
      • Major Requisite
    • Pharmaceutical Experiment II

      • Subject No 37106Class No 02
      • 3Year ( 1.5Credit , 3Hour) Tue 6~9 (PHM-A307)
      • Major Requisite
    • Pharmaceutical Experiment II

      • Subject No 37106Class No 03
      • 3Year ( 1.5Credit , 3Hour) Wed 6~9 (PHM-A307)
      • Major Requisite
    • Clinical Immunology

      • Subject No 37131Class No 01
      • 4Year ( 1.5Credit , 1.5Hour) Thu 5~5
    • Advanced Pharmaceutical Microbiology II

      • Subject No G16897Class No 01
      • Year ( 3Credit , 3Hour) Mon 4~5
Academic Background

Pohang Univ. of Science and Technology 이학박사(생명과학과)

Seoul Nat'l Univ. 이학사(미생물학과)

Work Experience

국립암센터 선임연구원 2004-03-01 ~ 2005-08-31

UNIVERSITY OF VIRGINIA CARTER IMMUNOLOGY CENTER 1998-10-01 ~ 2001-10-31